Fort Washington Investment Advisors Inc. reduced their stake in
Bio-Techne Corp (TECH) significantly, alongside other institutions like
JPMorgan Chase & Co., and Bamco Inc. Despite some under-performance, a variety of institutions including
Mairs & Power Inc., American Century Companies Inc., and
Capital Research Global Investors have continued to grow their position in TECH. TECH has launched an array of new
spatial biology products and continues to expand its
COMET suite for research and consumable earnings. The pace of
organic growth projections into FY27 for TECH remains attractive. Amid the mix of sales and acquisitions,
Cowen has maintained a 'buy' rating on TECH. Despite recent disappointments in earnings, hope remains buoyant for TECH due to its continuous
innovation in
AI Drug Discovery and its crucial partnerships with institutions like
the Wyss Center Geneva. The company has also recently declared a dividend, and released promising Q1 and Q2 fiscal 2026 results. Despite recent losses, TECH's stock has shown resilience and has recently bounced back.
Bio-Techne Corp TECH News Analytics from Wed, 25 Jun 2025 07:00:00 GMT to Sat, 28 Mar 2026 10:14:30 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor 3
